GlueTacs Therapeutics
Tuesday, June 04, 2024
Oncology
Company Presentation Theater 1
GlueTacs Therapeutics is a clinical stage biotech developing molecular glue degraders and PROTACs, as well as degrader-antibody conjugates. Our novel intellectual property enables best-in-class substrate specificity, and our library accelerates discovery. Altogether, our systematic approach integrates virtual design, synthesis, and substrate evaluation to unlock pathways previously deemed "undruggable", producing an unpartnered pipeline focused on refractory tumors and immune diseases.
Company Website:
http://We are in the process of building our website, but if you google us, you can see that we definitely exist :)
Lead Product in Development:
GT-919 (Phase 1, recurrent/refractory multiple myeloma)
GT-929 (Phase 1, recurrent/refractory non-hodgkin's lymphoma)
Both of the above are molecular glues with the potential to be best-in-class, with the main competitors being developed by BMS and C4 Therapeutics.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
8: (2 Phase 1, 2 with IND filings being synthesized, 1 preclinical candidate, 3 discovery)
Company HQ City
Shanghai
Company HQ State
Pudong
Company HQ Country
China
CEO/Top Company Official
Xiaobao Yang, PhD
Development Phase of Primary Product
Phase I
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())